Immix Biopharma Inc
IMMX2.590USD
-0.060-2.26%
Market hours （ET）Quotes delayed by 15 min
72.14MMarket Cap
LossP/E TTM
More Details of Immix Biopharma Inc Company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Company Info
Ticker SymbolIMMX
Company nameImmix Biopharma Inc
IPO dateDec 16, 2021
CEODr. Ilya Rachman, M.D., Ph.D.
Number of employees18
Security typeOrdinary Share
Fiscal year-endDec 16
Address11400 West Olympic Blvd.
CityLOS ANGELES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code90064
Phone18889581084
Websitehttps://immixbio.com/
Ticker SymbolIMMX
IPO dateDec 16, 2021
CEODr. Ilya Rachman, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-0.13%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+161.79%
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, May 15
Updated: Thu, May 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hsu (Jason)
17.45%
GKCC, LLC
11.64%
Rachman (Ilya M)
4.09%
Ng (Carey)
3.75%
Bleichroeder LP
3.05%
Other
60.03%
Shareholders
Shareholders
Proportion
Hsu (Jason)
17.45%
GKCC, LLC
11.64%
Rachman (Ilya M)
4.09%
Ng (Carey)
3.75%
Bleichroeder LP
3.05%
Other
60.03%
Shareholder Types
Shareholders
Proportion
Individual Investor
28.71%
Corporation
11.64%
Investment Advisor/Hedge Fund
7.98%
Investment Advisor
4.27%
Research Firm
0.06%
Venture Capital
0.05%
Other
47.29%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
2023Q2
46
9.35M
66.71%
-203.85K
2023Q1
40
9.11M
65.58%
-364.69K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hsu (Jason)
4.86M
17.45%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
11.64%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
4.09%
+2.18K
+0.19%
Jun 18, 2025
Ng (Carey)
1.05M
3.75%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
3.05%
--
--
Mar 31, 2025
Cable Car Capital LLC
779.36K
2.8%
-16.74K
-2.10%
Mar 31, 2025
The Vanguard Group, Inc.
698.54K
2.51%
--
--
Mar 31, 2025
Morris (Gabriel S)
583.04K
2.09%
+2.23K
+0.38%
Jun 18, 2025
Lynwood Capital Management Inc.
405.00K
1.45%
+405.00K
--
Mar 31, 2024
Adams (Helen C)
174.75K
0.63%
-227.00
-0.13%
Apr 22, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
